333 related articles for article (PubMed ID: 31546754)
1. miRNA Profiling for Early Detection and Treatment of Duchenne Muscular Dystrophy.
Hrach HC; Mangone M
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546754
[TBL] [Abstract][Full Text] [Related]
2. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy.
Zaharieva IT; Calissano M; Scoto M; Preston M; Cirak S; Feng L; Collins J; Kole R; Guglieri M; Straub V; Bushby K; Ferlini A; Morgan JE; Muntoni F
PLoS One; 2013; 8(11):e80263. PubMed ID: 24282529
[TBL] [Abstract][Full Text] [Related]
3. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
Hu J; Kong M; Ye Y; Hong S; Cheng L; Jiang L
J Neurochem; 2014 Jun; 129(5):877-83. PubMed ID: 24460924
[TBL] [Abstract][Full Text] [Related]
4. Circulating MicroRNAs in Duchenne Muscular Dystrophy.
Mousa NO; Abdellatif A; Fahmy N; Zada S; El-Fawal H; Osman A
Clin Neurol Neurosurg; 2020 Feb; 189():105634. PubMed ID: 31838454
[TBL] [Abstract][Full Text] [Related]
5. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
6. Duchenne muscular dystrophy: an updated review of common available therapies.
Salmaninejad A; Valilou SF; Bayat H; Ebadi N; Daraei A; Yousefi M; Nesaei A; Mojarrad M
Int J Neurosci; 2018 Sep; 128(9):854-864. PubMed ID: 29351004
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of Duchenne muscular dystrophy: the state of the art.
Messina S; Vita GL
Neurol Sci; 2018 Nov; 39(11):1837-1845. PubMed ID: 30218397
[TBL] [Abstract][Full Text] [Related]
8. miRNome profiling in Duchenne muscular dystrophy; identification of asymptomatic and manifesting female carriers.
Mousa NO; Sayed AA; Fahmy N; Elzayat MG; Bakry U; Abdellatif A; Zahra WK; Osman A
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34472584
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
10. Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy.
Coenen-Stass AML; Wood MJA; Roberts TC
Trends Mol Med; 2017 Nov; 23(11):989-1001. PubMed ID: 28988850
[TBL] [Abstract][Full Text] [Related]
11. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy].
Takeshima Y
Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856
[TBL] [Abstract][Full Text] [Related]
12. miRNAs as serum biomarkers for Duchenne muscular dystrophy.
Cacchiarelli D; Legnini I; Martone J; Cazzella V; D'Amico A; Bertini E; Bozzoni I
EMBO Mol Med; 2011 May; 3(5):258-65. PubMed ID: 21425469
[TBL] [Abstract][Full Text] [Related]
13. [Mutation-specific treatments for Duchenne muscular dystrophy].
Matsuo M; Takeshima Y
Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
15. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of exonic rearrangements and frame shifts in the dystrophin gene in Duchenne muscular dystrophy patients in a Saudi community.
Elhawary NA; Jiffri EH; Jambi S; Mufti AH; Dannoun A; Kordi H; Khogeer A; Jiffri OH; Elhawary AN; Tayeb MT
Hum Genomics; 2018 Apr; 12(1):18. PubMed ID: 29631625
[TBL] [Abstract][Full Text] [Related]
17. The Role of MicroRNA in the Pathogenesis of Duchenne Muscular Dystrophy.
Kiełbowski K; Bakinowska E; Procyk G; Ziętara M; Pawlik A
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892293
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy.
Meyers TA; Townsend D
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443395
[TBL] [Abstract][Full Text] [Related]
19. Novel free-circulating and extracellular vesicle-derived miRNAs dysregulated in Duchenne muscular dystrophy.
Catapano F; Scaglioni D; Maresh K; Ala P; Domingos J; Selby V; Ricotti V; Phillips L; Servais L; Seferian A; Groot I; Krom YD; Voit T; Verschuuren JJGM; Niks EH; Straub V; Morgan J; Muntoni F
Epigenomics; 2020 Nov; 12(21):1899-1915. PubMed ID: 33215544
[No Abstract] [Full Text] [Related]
20. Digital PCR quantification of miR-30c and miR-181a as serum biomarkers for Duchenne muscular dystrophy.
Llano-Diez M; Ortez CI; Gay JA; Álvarez-Cabado L; Jou C; Medina J; Nascimento A; Jimenez-Mallebrera C
Neuromuscul Disord; 2017 Jan; 27(1):15-23. PubMed ID: 27979502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
